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compared to the proportion method and MGIT 960, as well as the
cost associated with widespread implementation.
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Background: Tuberculosis (TB) remains one of themajor causes
f death from a single infectious agent worldwide. Of great con-
ern for TB control is the emergence of drug resistance. Since there
s no cure for some multidrug-resistant strains of Mycobacterium
uberculosis, there is concern that they may spread around the
orld, stressing the need for additional control measures, such
s new diagnostics, better drugs for treatment, and a more effec-
ive vaccine. Recent advances in molecular biology and molecular
pidemiology, and a better understanding of the molecular basis
f drug resistance in TB, have provided new tools for rapid diag-
osis; however, the high cost of most of these techniques, and
heir requirement for sophisticated equipment and skilled per-
onnel have precluded their implementation on a routine basis,
specially in low-income countries. To respond to the urgent need
or simple and rapid diagnostic tools at the point of treatment
n high-burden countries, a fully automated molecular test for
uberculosis case detection and drug resistance testing was devel-
ped through collaboration in a public–private partnership; Xpert
TB/RIF, an automated molecular test for Mycobacterium tuber-
ulosis (MTB) and resistance to rifampin (RIF), uses heminested
eal-timepolymerase chain-reaction (PCR) assay to amplify anMTB
peciﬁc sequence of the rpoB gene, which is probed with molecular
eacons for mutations within the rifampin-resistance determining
egion. Testing is carried out on the MTB/RIF test platform (Gen-
Xpert, Cepheid), which integrates sample processing and PCR in
disposable plastic cartridge containing all reagents required for
acterial lysis, nucleic acid extraction, ampliﬁcation, and amplicon
etection.
Methods: In the present mini review, some of these approaches
ill be reviewed and the feasibility for their implementation in
iagnostic laboratories will be discussed.
Results: No results as this paper is a mini review presentation
Conclusion: The resurgence of interest in the development of
ew tools for TB control, and the recent inﬂux of funding and
olitical support, it is likely that the next few years will see the
ntroduction of new diagnostic tools like molecular test (Hain Test,
ene Xpert,) into routine TB control programs and particularly in
igh disease burden, and resource-poor countries.
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Background: Multidrug-resistant (MDR) and extremely drug-
resistant (XDR) tuberculosis (TB) are a critical public health
problem in sub-Saharan Africa. Effective diagnostic technology to
identify drug resistant cases at treatment onset would eliminate
this problem, but availability of these tools remains limited in high
burden TB settings. Line probe assays, rapid polymerase chain reac-
tion (PCR) based tests would be a tool of choice.
Methods: From January to December 2010, all samples submit-
ted for routine drug sensitivity testing (DST) according to national
algorithm were tested by LED microscopy and culture on Lowen-
stein Jensen (LJ) at the National Reference Laboratory (NRL). DST
was done by proportion method and PCR on either sputum or iso-
lates. Laboratory turn-around time (TAT) was compared for the
three techniques and its impact on death rate before second-line
treatment initiation was assessed.
Results: 249 isolates were tested by the proportion method on
LJ culture; 144 (58%) isolates were tested by MTBDRplus tests on
culture and an additional 20 (8.03%) MTBDRplus tests were done
directlyonsputumsamples. In totalninetypatientswereconﬁrmed
MDR-TB.Themedian laboratory TATwas79days for theproportion
method, 50 days for the Genotype® MTBDRplus on culture and 3.5
days on sputum (p<0.01). Only 4 patients died before second-line
TB treatmentwas initiated. This represents a signiﬁcant decrease in
the death rate before initiation of second line treatment from 15%
in 2008, 12.5% in 2009 to 4.4% in 2010
Conclusion: In comparison with existing DST methods, the
GenoType® MTBDRplus assay reduced time to diagnosis and treat-
ment of MDRTB cases in Rwanda. This technique should be
scaled up and future studies are ongoing to evaluate GenoType®
MTBDRplus assay sensitivity and speciﬁcity for INH, RIF andMDRTB
